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Abstract
Background: A genome-wide scan in unrelated US Caucasians identified rs7001819 upstream of
farnesyl-diphosphate farnesyltransferase 1 (FDFT1) and multiple variants within catenin (cadherin-
associated protein), β-like 1 (CTNNBL1) to associate strongly with body mass index (BMI). The
most significantly associating variants within CTNNBL1 including rs6013029 and rs6020846 were
additionally confirmed to associate with morbid obesity in a French Caucasian case-control sample.
The aim of this study was to investigate the impact of these three variants on obesity, through
analyses of obesity-related quantitative traits, and case-control studies in large study samples of
Danes.
Methods: The FDFT1 rs7001819, CTNNBL1 rs6013029 and rs6020846 were genotyped, using
TaqMan allelic discrimination, in a combined study sample comprising 18,014 participants
ascertained from; the population-based Inter99 cohort (n = 6,514), the ADDITION Denmark
screening study cohort (n = 8,662), and a population-based sample (n = 680) and a type 2 diabetic
patients group (n = 2,158) from Steno Diabetes Center.
Results: Both CTNNBL1 variants associated with body weight and height with per allele effect sizes
of 1.0 [0.3–0.8] kg and 0.6 [0.2–0.9] cm, respectively, for the rs6020846 G-allele. No association
was observed with BMI and waist circumference. In case-control studies neither of the CTNNBL1
variants showed association with overweight, obesity or morbid obesity (rs6013029: Odds Ratio
(OR)overweight = 1.02 [0.90–1.16], ORobesity = 1.09 [0.95–1.25], ORmorbidobesity = 1.26 [0.91–1.74];
rs6020846: ORoverweight = 1.05 [0.93–1.18], ORobesity= 1.13 [1.00–1.28], ORmorbidobesity = 1.17 [0.86–
1.61]). However, in meta-analyses of the present and the previous study, both the rs6013029 T-
allele and the rs6020846 G-allele increased the risk of developing morbid obesity (rs6013029:
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ORcombined = 1.36 [1.12–1.64], p = 0.002; rs6020846: ORcombined = 1.26 [1.06–1.51], p = 0.01), and
obesity (rs6013029: ORcombined = 1.17 [1.04–1.31], p = 0.007; rs6020846: ORcombined = 1.17 [1.05–
1.30], p = 0.004).
The FDFT1 rs7001819 C-allele showed no association with obesity-related quantitative measures
or dichotomous measures of overweight, obesity and morbid obesity.
Conclusion: CTNNBL1 variants associated with body weight and height, and confer the risk of
developing obesity in meta-analyses combining the present and a previous study. FDFT1 rs7001819
showed no association with obesity, neither when analysing quantitative traits nor when
performing case-control studies of obesity.
Background
As a consequence of a changing environment and lifestyle,
the rates of obesity, are escalating throughout the world.
This poses a major problem towards human health
through the association with increased risk of several
chronic diseases, such as type 2 diabetes, hypertension
and cardiovascular diseases, leading to premature mortal-
ity. Since obesity results from a complex interplay
between several genetic and environmental risk factors,
the identification of single nucleotide polymorphisms
(SNPs) in susceptibility genes has been challenging using
traditional approaches, such as linkage scans and biologi-
cal candidate gene association studies, leaving the genetic
background of common obesity largely unknown. Tech-
nical advancements have, however, made genome-wide
association (GWA) studies feasible, which uses a hypoth-
esis-free approach to scan the entire human genome for
genetic variants associated with disease. These studies
have led to a breakthrough in the identification of novel
gene loci with modest effects on complex diseases.
Several GWA scans have been performed on obesity and
obesity-related phenotypes, and the most frequently iden-
tified gene loci is FTO [1-4], which has been consistently
replicated in numerous independent association studies
[5-14]. Other GWA studies have reported variants in the
proximity of INSIG2 [15,16] and within PFKP [2,16] as
novel obesity gene loci, however, attempts to replicate the
association for the INSIG2 variant have been inconsistent
[17-24], which also appears true for variation in PFKP
[17]. A recent initiative in the identification of obesity sus-
ceptibility genes is large-scale meta-analyses combining
data from different GWA studies. This has lead to the
identification of genetic variants downstream of MC4R,
exerting effects on body mass index (BMI), and waist cir-
cumference, which was further supported by an inde-
pendent GWA study [25].
A recent GWA scan in 1,000 US Caucasians with measures
available on BMI and fat mass, identified two novel obes-
ity gene loci in the proximity of FDFT1 (farnesyl-diphos-
phate farnesyltransferase 1) and CTNNBL1  (catenin
(cadherin-associated protein), β-like 1) [16]. The strong-
est association with BMI was observed for rs7001819 (p =
2 × 10-7) mapping approximately 1 kb upstream of
FDFT1, however, no association with fat mass was shown,
and therefore no further analyses were performed for this
variant. Eight SNPs within CTNNBL1 showed strong asso-
ciations with both BMI and fat mass, out of which five
(rs6013029, rs16986921, rs6020712, rs6020846,
rs6020395) were replicated in an independent French
Caucasian obesity case-control sample comprising 896
cases (BMI ≥ 40 kg/m2) and 2,916 controls (BMI < 25 kg/
m2). In both study groups rs6013029 exerted the largest
effect, conferring a per risk T-allele increase of 2.67 kg/m2
in BMI and 5.96 kg in fat mass, and a 1.42-fold increased
odds of morbid obesity comparing homozygous T-allele
carriers with homozygous G-allele carriers.
The link between FDFT1, CTNNBL1 and obesity is fairly
unknown. FDFT1 encodes the enzyme catalysing the first
step of cholesterol synthesis [26], whereas CTNNBL1
encodes a protein homolog to β-catenin responsible for
cell-to-cell adhesion and Wnt-signalling [27-29]. Expres-
sion profiles in the human protein atlas http://www.pro
teinatlas.net show that FDFT1 predominantly is expressed
in the colon, whereas CTNNBL1  is ubiquitously
expressed. Moreover, studies have revealed that CTNNBL1
is highly expressed in skeletal muscle responsible for
energy metabolism [27]. Linkage scans of obesity have
previously highlighted the chromosome 20q11 region,
which encompasses CTNNBL1, as a candidate region
[30,31], thus, further establishing the candidature of this
gene in the pathogenesis of obesity.
Replication of GWA findings in well-designed and statisti-
cally powered studies is essential to elucidate the impor-
tance of the proposed findings on obesity. Therefore, in
the present study, we genotyped rs7001819 near FDFT1
responsible for the strongest BMI association and two tag-
SNPs (rs6020846 and rs6013029) that according to Hap-
Map capture (r2cutoff = 0.8) the five replicated SNPs in
CTNNBL1 identified in the initial GWA study. The aim
was to elucidate whether the three variants associated withBMC Medical Genetics 2009, 10:17 http://www.biomedcentral.com/1471-2350/10/17
Page 3 of 9
(page number not for citation purposes)
obesity in large study samples of Danes, by examining
obesity-related quantitative traits, and by performing
case-control studies of overweight, obesity and morbid
obesity.
Methods
Subjects
The  FDFT1  rs7001819,  CTNNBL1  rs6013029 and
rs6020846 variants were genotyped in 18,014 individuals
ascertained from four different study groups; 1) the
Inter99 cohort, which is a population-based, randomized,
non-pharmacological intervention study of middle-aged
individuals for the prevention of ischemic heart disease (n
= 6,514), conducted at the Research Centre for Prevention
and Health in Glostrup, Copenhagen (ClinicalTrials.gov
ID-no: NCT00289237) [32,33]; 2) the ADDITION Den-
mark screening study cohort (Anglo-Danish-Dutch Study
of Intensive Treatment in People with Screen-Detected
Diabetes in Primary Care) (ClinicalTrials.gov ID-no:
NCT00237548) [34], which is a population-based, high-
risk screening and intervention study for type 2 diabetes in
general practice (n= 8,662); 3) a population-based group
of unrelated middle-aged individuals (n = 680) examined
at Steno Diabetes Center; and 4) unrelated type 2 diabetic
patients (n  = 2,158) sampled through the out-patient
clinic at Steno Diabetes Center. In the combined study
sample 1,914 had screen-detected and 2,302 had known
type 2 diabetes, 5,512 were normal weight, 7,458 were
overweight and 5,044 were obese, with 409 being mor-
bidly obese. All participants in study group 1 and 3 under-
went a standard 75 g oral glucose tolerance test. Type 2
diabetes and glucose tolerance were defined according to
the World Health Organization [35]. Overweight, obesity
and morbid obesity were defined as 25 kg/m2 ≤ BMI < 30
kg/m2, BMI ≥ 30 kg/m2 and BMI ≥ 40 kg/m2, respectively.
More information about the study groups is available in
Additional file 1. All study participants were Danes by
self-report, and informed written consent was obtained
from all subjects before participation. The studies were
approved by the regional Ethical Committees (ethics com-
mittee, Copenhagen County for study group 1, 3 and 4
and ethics committee, Aarhus County for study group 2)
and were in accordance with the principles of the Helsinki
Declaration.
Biochemical and anthropometric measures
In all four study groups body weight and height were
measured in light indoor clothes and without shoes. BMI
was defined as weight in kilograms divided by height in
meters squared (kg/m2). Waist circumference (cm) was
measured with subjects in standing position midway
between the iliac crest and the lower costal margin. In
study group 1, 3 and 4 blood samples were drawn after a
12-hour overnight fast and total cholesterol and high den-
sity lipoprotein (HDL) -cholesterol were determined
using enzymatic colorimetric methods (GPO-PAP and
CHOD-PAP; Roche Molecular Biochemicals, Mannheim,
Germany). In study group 2 fasting blood glucose was
measured on capillary whole blood using a HemoCue B-
glucose analyser (HemoCue AB, Ängelholm, Sweden) and
the Hitachi 971 system (Roche Diagnostics GmbH, Man-
nheim, Germany) was used to measure total serum cho-
lesterol and serum HDL-cholesterol.
Genotyping
FDFT1 rs7001819, CTNNBL1 rs6013029 and rs6020846
were genotyped in 18,014 Danes using TaqMan allelic dis-
crimination (KBioscience, Herts, UK). Genotyping success
rates were 93.1%, 97.3% and 97.1%, respectively, and the
minor allele frequencies (MAF) were 36.1%, 4.6% and
5.4%, respectively. The discordance rates between 1,185,
1,170 and 1,170 random duplicate samples were 0.42%,
0.17% and 0.43%, respectively. Genotype distribution
obeyed Hardy-Weinberg equilibrium for all three variants
p = 0.3, p = 0.06 and p = 0.5, respectively.
Statistical analysis
Homogeneity in the combined study sample, including
the population-based Inter99 cohort, the ADDITION
Denmark screening study cohort, the population-based
and type 2 diabetic patient groups from Steno Diabetes
Center, was evaluated for each of the three variants.
Homogeneity tests were performed by means of the Man-
tel-Haenszel method (fixed effect model) and revealed no
statistically significant heterogeneity between study
groups (rs7001819: p  = 0.7, rs6013029: p  = 1.0,
rs6020846: p = 0.8).
To test quantitative obesity-related traits for differences
between genotype groups a general linear model was
used, applying an additive and dominant model for each
variant and including adjustments for sex, age and BMI
when appropriate. Case-control studies of overweight,
obesity and morbid obesity were performed in the com-
bined study sample and separately in the population-
based Inter99 study sample, by applying logistic regres-
sion to examine differences in genotype distributions
between affected and unaffected subjects. An additive and
dominant model was applied and adjustments for sex and
age were introduced. Meta-analyses of the present and the
previous study were performed using allele frequencies,
applying general linear models with the Mantel-Haenszel
method. All analyses were performed in RGui version
2.6.2 [36], and p-values < 0.05 were considered signifi-
cant. Linkage Disequilibrium (LD) between markers was
evaluated using Haploview 4.1 http://
www.broad.mit.edu/mpg/haploview/. Statistical power
for the quantitative traits was estimated using simulations
(n = 5,000), where variance across genotypes were drawn
from phenotypes simulated to follow normal distributionBMC Medical Genetics 2009, 10:17 http://www.biomedcentral.com/1471-2350/10/17
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using empirical variances. The variance for adjustment
factors, estimated using residuals of linear models, was
also included in the model, assuming independency of
genotypes. Linear models were used both for simulating
and testing data, assuming additive models and using a
significance threshold of 0.05. The estimated power for
variants with a MAF of 5% was > 90% for per allele effect
sizes of 0.4 kg/m2 for BMI and 1.5 cm for waist circumfer-
ence.
Statistical power in case-control settings was determined
using the CaTS power calculator version 0.0.2. Using the
population-based Inter99 cohort as reference the preva-
lence of overweight, obesity and morbid obesity in the
Danish population was estimated to 39%, 17% and 1.3%,
respectively. This gives us a statistical power of 100% and
94% to detect associations with overweight and obesity,
respectively, for a variant with a MAF of 5% with a relative
risk of 1.2 and a statistical power of 53% to detect associ-
ation with morbid obesity, for a variant with a MAF of 5%
with a relative risk of 1.4.
Results
We aimed at replicating the observed association between
the CTNNBL1 rs6013029 T-allele, CTNNBL1 rs6020846
G-allele, and FDFT1 rs7001819 C-allele and measures of
obesity. The variants were investigated for influence on
quantitative obesity-related traits in the combined study
sample, excluding treated type 2 diabetic patients. Moreo-
ver, case-controls settings were used to investigate poten-
tial associations between the variants and overweight,
obesity and morbid obesity in the combined study sample
including type 2 diabetic patients.
The LD between the two CTNNBL1 variants was estimated
to r2 = 0.83 in the combined study sample. Neither variant
showed association with BMI nor waist circumference,
however, the rs6013029 T-allele and rs6020846 G-allele
associated with body weight (rs6013029: p  = 0.03;
rs6020846: p = 0.007) and height (rs6013029: p = 0.007;
rs6020846: p = 5 × 10-4), with rs6020846 exerting the larg-
est effect, with a per G-allele increase in body weight of 1.0
[0.3–1.8] kg and in height of 0.6 [0.2–0.9] cm, Table 1. In
case-control studies no statistically significant associa-
tions were observed when comparing the genotype distri-
bution between normal weight individuals and
overweight, obese or morbid obese individuals
(rs6013029: Odds Ratio (OR)overweight = 1.02 [0.90–1.16],
ORobesity = 1.09 [0.95–1.25], ORmorbidobesity = 1.26 [0.91–
1.74]; rs6020846: ORoverweight = 1.05 [0.93–1.18], ORobesity
= 1.13 [1.00–1.28], ORmorbidobesity = 1.17 [0.86–1.61]),
Table 2. However, for both variants, the risk allele fre-
quency increased with increasing degree of obesity, also
reflected in the relatively large effect sizes estimated by the
ORs, which are per allele increases in risk. We therefore
performed meta-analyses, based on available allele fre-
quencies, combining our data with data from the French
Caucasian obesity case-control sample used for replica-
tion in the initial study by Liu et al. [16]. Both CTNNBL1
variants associated with increased susceptibility to mor-
bid obesity (rs6013029: ORcombined = 1.36 [1.12–1.64], p
= 0.002; rs6020846: ORcombined = 1.26 [1.06–1.51], p =
0.01), Figure 1. Test of between-study homogeneity
showed no heterogeneity for either rs6013029 (p = 0.5) or
rs6020846 (p = 0.5). Moreover, a meta-analysis combin-
ing our data on obese individuals with the French Cauca-
sian morbid obesity data, also showed significant
associations for both variants (rs6013029: ORcombined =
1.17 [1.04–1.31], p = 0.007; rs6020846: ORcombined = 1.17
[1.05–1.30], p = 0.004), with no between-study heteroge-
neity (p = 0.1 and 0.2 respectively).
The FDFT1 rs7001819 C-allele showed no association
with BMI, body weight, waist circumference or height,
Table 1. Due to the involvement of FDFT1 in cholesterol
biosynthesis we extended the analyses to include meas-
ures of total cholesterol and HDL-cholesterol, but no dif-
ferences between genotype groups were observed (data
not shown). Moreover, no association was observed with
overweight, obesity or morbid obesity (ORoverweight =
1.02 [0.97–1.08], ORobesity = 0.99 [0.93–1.05], ORmor-
bidobesity = 0.99 [0.85–1.16]), Table 2.
To investigate the effect on a population-based level, anal-
yses of obesity-related traits were moreover performed in
the population-based Inter99 cohort. The association
with body weight and height remained significant for
CTNNBL1 rs6020846, while no associations were demon-
strated for FDFT1 rs7001819, Additional file 2.
Likewise case-control studies in the population-based
Inter99 cohort revealed no statistical association for any
of the variants (p-values ranged from 0.2–1.0), but as in
the combined study sample the rs6013029 T-allele and
rs6020846 G-allele frequencies increased with the degree
of obesity, Additional file 3. All three variants were ana-
lysed for influence on type 2 diabetes susceptibility in the
combined study sample, however, no associations were
observed, either with or without adjustments for BMI,
Additional file 4.
Discussion
We find that the CTNNBL1 rs6013029 T-allele and the
rs6020846 G-allele confer an increased risk of developing
obesity, especially morbid obesity. Moreover, significant
associations with increased body weight and height were
observed together with non-significant increases in the
measures of BMI and waist circumference for carriers of
the CTNNBL1 risk alleles. The FDFT1 rs7001819 C-allele,
on the other hand, did not associate with measures ofBMC Medical Genetics 2009, 10:17 http://www.biomedcentral.com/1471-2350/10/17
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obesity, neither in quantitative analyses nor in case-con-
trol studies.
This is consistent with the results from Liu and co-workers
[16], who in a GWA scan identified five SNPs in
CTNNBL1 as novel obesity variants, associating with both
BMI and fat mass as quantitative measures. These findings
were confirmed in independent case-control studies of
morbid obesity with a per allele OR ranking from 1.32–
1.43. The degree of LD between rs6013029 and
rs6020846 was higher in our combined study sample
than estimated by HapMap (r2 = 0.83 vs. 0.73), thus, the
results for these two variants are highly concordant; with
the rs6020846 G-allele exerting the largest effect on quan-
titative measures, and the rs6013029 T-allele on the risk
of developing morbid obesity.
Both CTNNBL1 variants associated with body weight and
height, with a per allele increase of 1.0 [0.3–1.8] kg and
0.6 [0.2–0.9] cm, respectively, for the rs6020846 G-allele.
Likewise, we see increasing measures of BMI and waist cir-
cumference as a consequence of increasing number of risk
alleles, however, not significant. The effect on BMI and
waist circumference was 0.17 [-0.1–0.4] kg/m2 and 0.5 [-
0.1–1.2] cm, respectively, for the rs6020846 G-allele,
which is smaller than the effects observed by Liu et al.
[16]. Thus, the lack of statistical significant replication
might be due to lack of power to detect these effect sizes.
In case-control settings rs6013029 we observed increasing
MAF with increasing degree of obesity, with a per allele
OR of 1.26 [0.91–1.74] when analysing morbid obesity,
which is in the range of the OR observed by Liu et al. [16].
However, the increased risk did not reach statistical signif-
icance, probably due to the relatively low number of mor-
bidly obese individuals in our study sample. Since our
combined study sample is not designed to analyse morbid
obesity, we are underpowered (< 90%) to detect an asso-
ciation with a relative risk below 1.65.
That variants in CTNNBL1 could confer risk to the devel-
opment of morbid obesity is supported by the meta-anal-
yses performed including the present study and the
French Caucasian obesity case-control sample used for
replication in the initial study [16]. Combining the two
studies a significant overall association with a combined
per allele OR of 1.36 [1.12–1.64] for the rs6020846 G-
allele and 1.26 [1.06–1.51] for the rs6013029 T-allele was
observed. Moreover, our analysis of obesity for rs6013029
showed borderline significance (p = 0.06) with a 1.13-fold
per allele increase in the risk of developing obesity. When
combining our data on obese individuals with the French
Caucasian morbid obesity data used for replication by Liu
et al. [16], in a meta-analysis, a significant association is
also observed with a combined OR of 1.17 [1.04–1.31],
suggesting that CTNNBL1 is likely be a true obesity gene
Meta-analyses of morbid obesity for CTNNBL1 rs6013029 and rs6020846 Figure 1
Meta-analyses of morbid obesity for CTNNBL1 rs6013029 and rs6020846. Estimated odds ratios (OR) [95% CI] for 
morbid obesity for minor allele carriers of CTNNBL1 rs6013029 and rs6020846, in combined analyses of the present, and a pre-
vious study [16]. No heterogeneity between the two studies was observed (p = 0.5). The study by Liu et al. [16] included 2,669 
lean controls and 877 morbidly obese cases for both variants and the present study included 5,190 controls and 399 cases for 
rs6013029 and 5,188 controls and 394 cases for rs6020846.
0.8 0.9 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8
Odds ratio (95% CI)
Both studies
Present study
Liu et al. 2008 [16]
Combined OR = 1.36 [1.12-1.64] (p = 0.002)
0.8 0.9 1.1 1.2 1.3 1.4 1.5 1.6 1.7
Odds ratio (95% CI)
Combined OR = 1.26 [1.06-1.51] (p = 0.01)
rs6013029 rs6020846BMC Medical Genetics 2009, 10:17 http://www.biomedcentral.com/1471-2350/10/17
Page 6 of 9
(page number not for citation purposes)
conferring risk of developing both obesity and morbid
obesity.
Regarding FDFT1 we failed to demonstrate an association
between the rs7001819 C-allele and measures of obesity,
both when investigating quantitative phenotypes includ-
ing BMI and waist circumference and dichotomous BMI
cut-offs of overweight, obesity and morbid obesity, con-
sistent with the fact that no association with fat mass was
observed in the initial study [16].
Investigating available GWA data on quantitative traits
from the Broad Institute Diabetes Genetic Initiative (DGI;
http://www.broad.mit.edu/sections/science/projects/dia
betes-genetics-initiative), no association with body weight
or height was observed for the two CTNNBL1 variants,
either when looking at BMI and waist circumference [37].
Data for obesity case-control studies are unfortunately not
available, and could therefore not be included in the
present meta-analysis. FDFT1  rs7001819 was not
included in the DGI data, neither were markers in high LD
with the variant. The gene was represented by other mark-
ers, however, none of these showed any association with
obesity-related quantitative traits [37], suggesting that var-
iants at the FDFT1 locus do not associate with obesity.
From our studies we can exclude FDFT1 rs7001819 as a
susceptibility variant conferring risk to obesity in the Dan-
ish population. Contrary, meta-analyses indicates that
both the CTNNBL1 rs6013029 T-allele and the rs6020846
G-allele confer the risk of being obese and especially mor-
bidly obese, however, large well-powered studies
designed to analyse especially morbid obesity are needed
to validate this observation.
Conclusion
Both CTNNBL1 variants associated with body weight and
height, whereas BMI and waist circumference was insignif-
icantly elevated with increasing number of obesity risk
alleles. Likewise, the MAF and OR increased with increas-
ing degree of obesity in case-control studies of overweight,
obesity and morbid obesity, and meta-analyses showed
that both the rs6013029 T-allele and the rs6020846 G-
allele significantly increases the risk of developing obesity,
especially morbid obesity. The FDFT1 rs7001819 C-allele
showed no association with neither quantitative nor
dichotomous measures of obesity.
Abbreviations
BMI: body mass index; CI: confidence interval; CTNNBL1:
catenin (cadherin-associated protein), β-like 1; FDFT1:
farnesyl-diphosphate farnesyltransferase 1; GWA:
Table 1: Quantitative obesity-related measures in the combined study sample
n 
(men/woman)
Age 
(years)
BMI 
(kg/m2)
Body weight 
(kg)
Waist circumference 
(cm)
Height 
(cm)
CTNNBL1 rs6013029 GG 13,579 (7,113/6,466) 54 ± 10 27.5 ± 4.8 81.0 ± 16.2 92.5 ± 14.3 171.2 ± 9.2
GT 1,318 (702/616) 55 ± 10 27.7 ± 4.9 82.0 ± 16.5 93.1 ± 14.5 171.8 ± 9.1
TT 22 (9/13) 56 ± 9 27.6 ± 4.5 80.2 ± 12.5 91.9 ± 11.9 170.8 ± 7.3
Per allele 
effect size
(95% CI)
0.16
(-0.10–0.42)
0.89
(0.08–1.69)
0.43
(-0.26–1.12)
0.48
(0.13–0.82)
Padd 0.2 0.03 0.2 0.007
Pdom 0.2 0.03 0.2 0.009
CTNNBL1 rs6020846 AA 13,317 (6,972/6,345) 54 ± 10 27.5 ± 4.8 80.9 ± 16.2 92.5 ± 14.3 171.2 ± 9.2
AG 1,527 (821/706) 55 ± 10 27.7 ± 4.9 82.1 ± 16.5 93.2 ± 14.3 171.9 ± 9.1
GG 42 (23/19) 57 ± 9 27.8 ± 4.5 83.7 ± 15.4 94.5 ± 14.0 173.2 ± 8.4
Per allele 
effect size
(95% CI)
0.17
(-0.07–0.41)
1.02
(0.28–1.76)
0.54
(-0.09–1.17)
0.56
(0.25–0.88)
Padd 0.2 0.007 0.1 5 × 10-4
Pdom 0.2 0.008 0.1 0.001
FDFT1
rs7001819
TT 5,929
(3,062/2,867)
55 ± 10 27.5 ± 4.9 80.8 ± 16.3 92.4 ± 14.4 171.1 ± 9.2
TC 6,823 (3,597/3,226) 54 ± 10 28.0 ± 4.9 81.3 ± 16.4 92.4 ± 14.4 171.5 ± 9.3
CC 1,886 (1,021/865) 55 ± 10 27.5 ± 4.8 81.0 ± 15.8 92.6 ± 13.9 171.3 ± 9.1
Per allele 
effect size
(95% CI)
0.01
(-0.10–0.13)
0.06
(-0.29–0.41)
0.03
(-0.28–0.33)
0.06
(-0.09–0.21)
Padd 0.8 0.8 0.9 0.4
Pdom 0.6 0.3 0.5 0.07
Data are means ± standard deviation. p-values were calculated assuming a additive (padd) and a dominant (pdom) model for all variants. Known type 
2 diabetic patients were excluded from the analyses. Per allele effect sizes was calculated using linear models assuming an additive model. 
Adjustments were made for the effect of age and sex.BMC Medical Genetics 2009, 10:17 http://www.biomedcentral.com/1471-2350/10/17
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genome-wide association; LD: linkage disequilibrim;
MAF: minor allele frequency; OR: odds ratio; SNP: single
nucleotide polymorphism.
Competing interests
CH Andreasen, MS Mogensen, K Borch-Johnsen, O Peder-
sen and T Hansen hold stock in Novo Nordisk and K
Borch-Johnsen, O Pedersen and T Hansen have received
lecture fees from pharmaceutical companies. All other
authors declare that there is no competing interest associ-
ated with this manuscript.
Authors' contributions
The concept and idea regarding the epidemiological stud-
ies underlying the study populations analysed in the
genetic study was conceived by TJ, KBJ, AS, TL, OP and TH.
The collection of study subjects was planned and per-
formed by TJ, KBJ, AS, TL, OP and TH.
The original hypothesis regarding the genetic study was
conceived by CHA and MSM and approved by OP and TH.
Detail planning of analyses and study design was per-
formed by CHA and MSM and approved by OP and TH.
CHA, MSM, KA, LH, OP and TH contributed to the estab-
lishment of study population databases specific for this
study. Statistical analyses in association studies were per-
formed by CHA and MSM. The first manuscript was writ-
ten by CHA and MSM with equal contribution and the
final draft was finalised by CHA, OP and TH. All authors
revised the manuscript and contributed to the discussion.
Additional material
Additional file 1
Supplementary Table 1. Subjects included in the analyses stratified 
according to study group.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-10-17-S1.doc]
Additional file 2
Supplementary Table 2. Quantitative obesity-related measures in the 
population-based Inter99 cohort.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-10-17-S2.doc]
Table 2: Case-control studies of overweight, obesity and morbid obesity in the combined study sample
CTNNBL1 rs6013029 n 
(men/women)
Genotype distribution 
n GG/GT/TT (%)
MAF 
(95% CI)
padd pdom ORadd 
(95% CI)
Controls 5,190 (2,271/3,019) 4,740/444/6
(91.4/8.5/0.1)
4.4
(4.0–4.8)
Overweight cases 7,229 (4,496/2,733) 6,589/629//11
(91.1/8.7/0.2)
4.5
(4.2–4.9)
0.7 0.8 1.02
(0.90–1.16)
Obese cases 4,928 (2,543/2,385) 4,464/456/8
(90.5/9.3/0.2)
4.8
(4.4–5.2)
0.2 0.2 1.09
(0.95–1.25)
Morbid obese cases 399
(135/264)
356/43/0
(89.1/10.9/0.0)
5.4
(3.9–7.2)
0.2 0.1 1.26
(0.91–1.74)
CTNNBL1 rs6020846 n
(men/women)
Genotype distribution 
n AA/GA/GG (%)
MAF
(95% CI)
padd pdom ORadd
(95% CI)
Controls 5,188 (2,169/3,019) 4,673/504/11
(90.1/9.7/0.2)
5.1
(4.7–5.5)
Overweight cases 7,204 (4,492/2,712) 6,448/738/18
(89.4/10.3/0.2)
5.4
(5.0–5.8)
0.5 0.5 1.05
(0.93–1.18)
Obese cases 4,905 (2,533/2,372) 4,358/531/16
(88.8/10.9/0.3)
5.7
(5.3–6.2)
0.06 0.06 1.13
(1.00–1.28)
Morbid obese cases 394
(134/260)
348/46/0
(88.2/11.8/0.0)
5.8
(4.3–7.7)
0.3 0.2 1.17
(0.86–1.61)
FDFT1 rs7001819 n
(men/women)
Genotype distribution  
n TT/TC/CC (%)
MAF
(95% CI)
padd pdom ORadd
(95% CI)
Controls 5,089
(2,123/2,966)
2,084/2,367/638
(40.9/46.5/12.6)
35.8
(34.9–36.7)
Overweight cases 7,078
(4,391/2,687)
2,843/3,281/954
(40.2/46.3/13.5)
36.7
(35.9–37.5)
0.5 0.6 1.02
(0.97–1.08)
Obese cases 4,810
(2,491/2,319)
1,963/2,258/589
(40.6/47.1/12.3)
35.7
(34.8–36.7)
0.6 0.9 0.99
(0.93–1.05)
Morbid obese cases 387
(131/256)
158/184/45
(41.0/47.5/11.5)
35.4
(32.0–38.9)
0.9 0.9 0.99
(0.85–1.16)
Data are number of subjects, divided into genotype groups (% in each group), frequencies of the minor allele (MAF) in percentages (95% CI) and 
odds ratio (OR) for an additive (add) model (95% CI). Since the CTNNBL1 variants are rather rare, the p-values are given for both an additive and 
dominant (dom) model. Differences in genotype distribution were evaluated using logistic regression. p-values were adjusted for age and sex. 
Controls were defined as BMI < 25 kg/m2, overweight cases as 25 kg/m2 ≤ BMI < 30 kg/m2, obese cases as BMI ≥ 30 kg/m2 and morbid obese cases 
as BMI ≥ 40 kg/m2.BMC Medical Genetics 2009, 10:17 http://www.biomedcentral.com/1471-2350/10/17
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